European Journal of Clinical Microbiology & Infectious Diseases - Call for Papers: Recent developments on beta-lactam and beta-lactamase inhibitor combinations: susceptibility evaluation and resistance mechanisms

The European Journal of Clinical Microbiology and Infectious Diseases is seeking submissions for a collection on "Recent developments on beta-lactam/beta-lactamase inhibitor combinations: susceptibility evaluation and resistance mechanisms", edited by Drs. Alejandro Beceiro (this opens in a new tab) and Jorge Arca-Suarez (this opens in a new tab) (Servicio de Microbilogía, Instituto de Investigación Biomédica da Coruña, Complejo Hospitalario Unversitario A Coruña, Spain).

The recent development of novel therapeutic drugs aiming to provide novel therapeutic alternatives against infections caused by the so-called multidrug-resistant isolates opens a totally novel landscape in the bacterial-related infectious diseases field.

Indeed, although very few therapeutic options were still available in many infectious contexts and in many geographical areas quite recently, there is currently a new wave of therapeutical options that are not yet or will soon be available. Several industrial companies have developed drugs that possess new mode of action or of penetration into the bacterial cell (e.g., the siderophore cephalosporin cefiderocol), and besides there is a tremendous development of ß-lactamase inhibitors that will provide new alternatives when combined with some ß-lactam antibiotics (being either old or new molecules).

Those ß-lactamase inhibitors belonging to several molecule classes (i.e., diazabicycloonate-derived, boronic acid-derived, etc.) are currently under clinical evaluation, implying that fundamental and clinical investigations are currently required to i) evaluate their potency in association with some other antibacterial agents, ii) identify any possible resistance mechanisms, and iii) perform some corresponding epidemiological/surveillance surveys to better evaluate their overall efficacy and added value in different epidemiological contexts.

All those studies are crucial and rapidly required to assure their wise and meaningful usage, to inform about potential weaknesses, and soon contribute to their optimal management through a well-defined stewardship.

Such evaluations and investigations will find perfect room in this article collection, and we will be glad to read your contribution on this topic.

Please submit directly to the journal, stating in your cover letter that it is for the “Recent developments on beta-lactam / beta-lactamase inhibitor combinations: susceptibility evaluation and resistance mechanisms” topical collection. Upon submission, you will be asked if your manuscript is for a collection. Please answer “Yes” and select the name of the collection in the drop-down menu.

You can e-mail your pre-submission queries to barbara.zoehrer@springernature.com (this opens in a new tab).

Submit your manuscript (this opens in a new tab)

Submission guidelines (this opens in a new tab)

Manuscript editing services (this opens in a new tab)